You are here

MOLECULAR PROFILING ARRAY FOR CANCER SPECIFIC PROTEINS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44CA096061-01
Agency Tracking Number: CA096061
Amount: $140,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ARCHEMIX CORPORATION 1 HAMPSHIRE ST
CAMBRIDGE, MA 02139
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARTIN STANTON
 () -
 STANTON@ARCHEMIX.COM
Business Contact
 MARTIN STANTON
Phone: (617) 475-2322
Email: STANTON@ARCHEMIX.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant):
We will develop a protein detection chip that will allow parallel detection of proteins, including their modified forms. These chips, or molecular profiling arrays, will specifically focus on cancer related targets. This tool will allow researchers and clinicians to generate a molecular profile of cellular extracts.
Our core technology, Riboreporters, are allosteric ribozymes whose activity is regulated by an effector molecule. By monitoring the activity of the Riboreporter, it is possible to infer the level of the effector (or target) molecule. Previously, it has been shown that Riboreporters can respond to a wide range of targets, including small molecules and proteins. During phase I, we will demonstrate a 2-element Riboreporter chip capable of specifically detecting ERK and phosphorylated-ERK in cellular extracts. This demonstration will allow us to critically evaluate important aspects of this technology, including: a) the ability to generate Riboreporters to cancer related targets; b) the ability to differentiate modified forms of the same protein; c) the
ability to use Riboreporters in a high-throughput, chip-based format and d) the ability to use this chip in complex cellular extracts. During phase II, we will develop a larger scale chip for the analysis of cancer related targets.

PROPOSED COMMERCIAL APPLICATION: This technology will be useful for cancer diagnostics, cancer research and the development of new therapeutic compounds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government